Trastuzumab pamirtecan vs Tucatinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HER2-Positive Breast Cancer

Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline

Trastuzumab pamirtecan

Developed by BioNTech under a licence from DualityBio Inc.

Phase 3 in HER2-Positive Breast Cancerantibody-drug conjugate
Partial signal

NCT06265428 · Phase 3 · active, not recruiting

Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT06265428 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Up to approximately 24 months.): NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. (met)

Result source: NCT06265428

Tucatinib

Marketed by Pfizer and partners

Approved in HER2-Positive Breast Cancersmall molecule
Reliable signal

NCT03975647 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked, placebo-controlled trial of 466 patients, with progression-free survival as the primary endpoint. The primary comparison reached statistical significance in favor of tucatinib (hazard ratio 0.759, p=0.0163).

Next expected readout: December 2026 · NCT06016387 (registry estimate)

Reported efficacy

Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to approximately 3 years): HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. (met)

Result source: NCT05132582

Results for HER2-Positive Breast Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Trastuzumab pamirtecan
NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. NCT06265428 · Phase 3 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tucatinib

PFS 9.5 vs 7.4 placebo months
time to event · months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 7 more results
7.8 vs 5.7 placebo months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
9.6 vs 7.4 placebo months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
7.8 vs 5.5 placebo months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
7.8 vs 5.6 placebo months
NCT02614794 · Phase 2 · combination
7.6 vs 5.4 placebo months
NCT02614794 · Phase 2 · combination
7.5 vs 4.3 placebo months
NCT02614794 · Phase 2 · combination
7.6 vs 4.9 placebo months
NCT02614794 · Phase 2 · combination
ORR 42% (n=188) vs 36.1% (n=191) placebo
responder rate · % of participants
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 3 more results
47.3% (n=182) vs 41.1% (n=185) placebo
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
40.7% (n=273) vs 23.4% (n=137) placebo
NCT02614794 · Phase 2 · combination
41.4% (n=280) vs 23% (n=139) placebo
NCT02614794 · Phase 2 · combination
Overall Survival 21.9 vs 17.4 placebo months
time to event · months
NCT02614794 · Phase 2 · combination
show 1 more result
24.7 vs 19.2 placebo months
NCT02614794 · Phase 2 · combination
Duration of Response 8.3 vs 6.3 placebo months
time to event · months
NCT02614794 · Phase 2 · combination
show 1 more result
7 vs 6.9 placebo months
NCT02614794 · Phase 2 · combination
Clinical Benefit 59.8% (n=410) vs 38.1% (n=202) placebo
responder rate · % of participants
NCT02614794 · Phase 2 · combination
show 1 more result
58% (n=410) vs 37.6% (n=202) placebo
NCT02614794 · Phase 2 · combination
Available safety results

Tucatinib

Dropout rate
34.6%
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
n/a: no completion milestone
NCT02614794 · Phase 2 · combination
Discontinued due to AEs
—
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
—
NCT02614794 · Phase 2 · combination
Serious AEs
30.3%
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
30.7%
NCT02614794 · Phase 2 · combination
Most frequent reported AEs
nausea 65.4% (placebo 48.5%)
diarrhoea 56.7% (placebo 26.6%)
fatigue 48.9% (placebo 36.5%)
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
diarrhoea 81.7% (placebo 53.8%)
palmar-plantar erythrodysaesthesia syndrome 65.6% (placebo 53.3%)
nausea 60.1% (placebo 44.2%)
NCT02614794 · Phase 2 · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Trastuzumab pamirtecan's landscape · Tucatinib's landscape